Astellas’ $3 billion gene therapy deal steadies investors after stalled Roche acquisition
December 03, 2019 at 11:11 AM EST
Astellas Pharma Inc.’s $3 billion acquisition of Audentes Therapeutics is a strong indicator that the pharmaceutical industry’s march into gene therapy development isn’t going to slow down in 2020.